Novo Nordisk Foundation makes 5.5 billion kroner commitment
The Danish Novo Nordisk Foundation is allocating up to 5.5 billion Danish kroner ($860 million) to the BioInnovation Institute (BII), a Copenhagen-based organization set up to accelerate life science and deep tech innovation. The long-term funding framework runs from 2026 to 2035 and is intended to help BII support more entrepreneurs, expand into new scientific areas, and widen its European footprint.
BII said it has helped create and develop more than 130 companies since it was established in 2018 and has attracted more than 7 billion kroner in external funding. The institute’s programs include Venture Lab, Bio Studio, and BII Quantum Lab, with the new backing also expected to support expansion into fields such as AI and quantum technologies, alongside continued focus on biotech start-ups.
In a recent Venture Lab cohort, BII-backed companies included protein engineering player Troya Therapeutics and Sulis Therapeutics, which is developing STING inhibitors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze